Novavax | NVAX - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Adma Biologics USD 136.02M 2.13M 2026-06
Agenus USD 18.74M 16.26M 2026-06
AstraZeneca USD 4.89B 2.67B 2026-06
BioCryst Pharmaceuticals USD 154.97M 16.62M 2026-06
Cassava Sciences USD 86.57M 8.93M 2026-03
Geron USD 62.64M 6.25M 2026-06
GlaxoSmithKline GBP 3.44B 292M 2026-03
MannKind USD 52.93M 95K 2026-06
Merck USD 6.85B 1.52B 2026-06
Minerva Neurosciences USD 82.3M 70.02M 2025-12
Moderna USD 1.72B 185M 2026-06
Novartis USD 6.88B 2.68B 2026-03
Novavax USD 191.46M 36.9M 2026-06
Pfizer USD 976M 727M 2026-06
Sanofi EUR 6.35B 806M 2026-06
Sarepta Therapeutics USD 571.15M 106.7M 2026-06
TG Therapeutics USD 612.25M 170.04M 2026-06